# Leads Biolabs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/leads-biolabs

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.leadsbiolabs.com
- Total disclosed funding: $145M
- Latest round: Series C (Oct 8, 2021)
- Investors on record: 25

## About

Based in Nanjing, China, and founded in 2014, Nanjing Violizhibo Biotech Co., Ltd., d.b.a. Leads Biolabs is an antibody-drug developer and engaged in research and development of original antibody drugs for anti-tumor, treatment of infectious diseases or autoimmune, and more. In October 2021, Leads Biolabs raised USD 100 million in a Series C funding led by Zhengxingu Capital, with participation from Ansett Securities, Beijing Longpan Investment Management Consulting Center, DYEE Capital, Rongchang Capital, Shenzhen Capital Group, Zhenji Capital, HanKang Capital, Houxin Asset, Huaige Capital, Jiantou Zhongxin Asset Management Co., Ltd., Nanjing Venture Capital, New Silk Road Investment, and Shanghai Zhuangzhong Venture Investment. Leads Biolabs has raised a total of USD 144.7 million in funding. Leads Biolabs provides an Antibody Discovery platform and Dual Multispecific Antibody platform. The Antibody Discovery platform integrates and utilizes internal and external discovery platforms to discover antibodies in combination with development progress, target characteristics, and required multispecies antibody design. The Dual Multispecific Antibody platform provides MOA or synthetic molecules by combining different targets. In addition, the company offers ADCC and CDC enhanced antibodies, process cell strains, vitro drug efficacy assessment and CMC. ADCC and CDC enhanced antibodies are molecules with better CDC and ADC effects compared to commercial antibodies. Leads Biolabs has several products in the clinical stage, including LBL-007 (LAG-3 monoantiob), LBL-003 (TIM-3 monoantiob), LBL-015 (PD-1/TGF beta dual resistance), and LBL-024 (PD-L1/4-1BB dual resistance). Leads Biolabs plans to use its proceeds from a Series C funding to accelerate the clinical research of its antibody-drug pipeline and its follow-up projects’ preclinical research. In July 2017, Leads Biolabs raised USD 69 million in pre-IPO funding from new Loyal Valley Capital, Gaoyi Investment, and E Fund Management Co.,Ltd.

## Funding rounds

- Series C, Oct 8, 2021, $100M — Nanjing Venture Capital, DYEE Capital, Rongchang Capital, Shenzhen Capital Real Estate Fund, Houxin Asset, Beijing Longpan Investment Management Consulting Center, Hankang Capital, Huaige Capital, Shanghai Zhuangzhong Venture Investment, New Silk Road Investment, Jiantou Zhongxin Asset Management Co., Ltd., Zhengxingu Capital, Ansett Securities, Zhenji Capital
- Series C, Oct 29, 2020, $30M — KPC Pharmaceuticals, NSR Wealth Management, GoldHold Wisdom Venture Capital, Yangtze River Capital, Huafang Capital, Huaige Capital, Ennovation Ventures, Entropy Asset Management, Million Capital
- Series C, Apr 20, 2019, $15M — New Vision Ventures, CCB Private Equity Investment Management, Huafang Capital, Huaige Capital
- Series A, Jul 4, 2017 — Nanjing Venture Capital, New Vision Ventures, Co-Win Ventures, CCB Private Equity Investment Management
- Angel, Dec 8, 2015 — Co-Win Ventures, Shanghai Zhuangzhong Venture Investment

## Investors

- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Angel, Series A
- Shanghai Zhuangzhong Venture Investment — Angel, Series C
- Nanjing Venture Capital (https://capitalatlas.ai/funds/nanjing-venture-capital) — Series A, Series C
- New Vision Ventures (https://capitalatlas.ai/funds/new-vision-ventures) — Series A, Series C
- CCB Private Equity Investment Management (https://capitalatlas.ai/funds/ccb-private-equity-investment-management) — Series A, Series C
- Huafang Capital (https://capitalatlas.ai/funds/huafang-capital) — Series C
- Huaige Capital (https://capitalatlas.ai/funds/huaige-capital) — Series C
- KPC Pharmaceuticals — Series C
- NSR Wealth Management (https://capitalatlas.ai/funds/nsr-wealth-management) — Series C
- GoldHold Wisdom Venture Capital (https://capitalatlas.ai/funds/goldhold-wisdom-venture-capital) — Series C
- Yangtze River Capital (https://capitalatlas.ai/funds/yangtze-river-capital) — Series C
- Ennovation Ventures (https://capitalatlas.ai/funds/ennovation-ventures) — Series C
- Entropy Asset Management — Series C
- Million Capital — Series C
- DYEE Capital (https://capitalatlas.ai/funds/dyee-capital) — Series C
- Rongchang Capital — Series C
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series C
- Houxin Asset — Series C
- Beijing Longpan Investment Management Consulting Center — Series C
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series C
- New Silk Road Investment — Series C
- Jiantou Zhongxin Asset Management Co., Ltd. — Series C
- Zhengxingu Capital — Series C
- Ansett Securities — Series C
- Zhenji Capital — Series C